Stocktoria
TransMedics Group, Inc. TMDX
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2019-05-02
TransMedics Group, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $31.4M |
| Gross profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M |
| R&D expense | $69.1M | $56.0M | $36.1M | $26.8M | $22.3M |
| SG&A expense | $185.2M | $168.6M | $119.6M | $69.9M | $38.3M |
| Operating income | $108.6M | $37.5M | -$28.7M | -$31.4M | -$39.4M |
| Interest expense | — | — | $10.8M | $3.7M | $3.9M |
| Income tax | -$82.8M | $316,000 | -$1.6M | $66,000 | — |
| Net income | $190.3M | $35.5M | -$25.0M | -$36.2M | -$44.2M |
| EPS (diluted) | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 |
| Operating cash flow | $192.8M | $48.8M | -$13.0M | -$45.8M | -$28.9M |
| Free cash flow | $133.6M | -$80.9M | -$164.9M | -$57.7M | -$32.4M |
| Cash & equivalents | — | — | $394.8M | $201.2M | $25.6M |
| Inventory | $48.9M | $46.6M | $44.2M | $20.6M | $14.9M |
| Total assets | $1.1B | $804.1M | $706.0M | $277.1M | $134.9M |
| Total liabilities | $595.3M | $575.5M | $568.8M | $89.8M | $67.0M |
| Shareholders' equity | $473.1M | $228.6M | $137.2M | $187.4M | $67.9M |
Source: SEC EDGAR filings · CIK 0001756262 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.